Gilead Sciences is a highly cash-generative, mature biopharma business anchored by its dominant HIV franchise. While top-line growth is constrained by patent maturities and competition, immense free cash flow generation easily supports a robust dividend and strategic oncology acquisitions. Fair value range: low $103, high $163, with mid-point at $132.
Stock analysis
Gilead Sciences Inc.GILD Gilead Sciences Inc. fair value $132–$163
Englische Quelle wird angezeigt, während wir übersetzen
Dieser Bericht wurde noch nicht übersetzt. Aktualisieren Sie in ein paar Minuten, sobald die Übersetzungswarteschlange aufgeholt hat.
§1 Zusammenfassung
Fairly valued with a synthesized target of $132.47 compared to a current price of $134.06.
Dominant but mature HIV franchise faces long-term growth constraints and patent expirations.
Immense free cash flow easily supports a robust dividend and ongoing strategic oncology investments.
Near-term multiple expansion requires significant commercial breakthroughs in the oncology pipeline.
Fair value
$132
Margin of safety
-1.2%
Confidence
88/100
Moat
6.5/10
Educational analysis only — not financial advice. Always do your own due diligence.
$134.06Price
FV $132.47
High $163
Gilead Sciences is a highly cash-generative, mature biopharma business anchored by its dominant HIV franchise. While top-line growth is constrained by patent maturities and competition, immense free cash flow generation easily supports a robust dividend and strategic oncology acquisitions.
Intangible Assets (Patents)
Intangible Assets (Patents)
Scale
Scale
Cycle upside
Accelerated approval of novel oncology therapies.
§2 Bärenszenario
A stress test scenario combining significant margin compression and revenue stagnation yields a fair value floor around $92-$102, anchored by sustainable dividend yields but penalizing the lack of top-line growth.
Wie diese These scheitern kann
Biktarvy LOE Collapse
· High
Rapid market share loss following the loss of exclusivity for Biktarvy without adequate replacement from the oncology pipeline.
FV impact
Down to ~$102
Trigger
Medium-Term
Oncology Pipeline Failure
· Medium
Late-stage clinical trial failures for key oncology assets fail to offset the impending revenue decay in virology.
FV impact
Down to ~$108
Trigger
Near-Term
Aggressive Pricing Reform
· Medium
Severe regulatory pricing pressures in the core HIV portfolio significantly compress operating margins.
FV impact
Down to ~$115
Trigger
Near-Term
Frühwarnsignale zur Überwachung
Kennzahl
Aktuell
Auslöseschwelle
Decelerating revenue growth in the core HIV franchise.
Monitor
Deterioration versus the report thesis
Clinical trial setbacks in the oncology pipeline.
Monitor
Deterioration versus the report thesis
Contraction of operating margins below historical averages.
Monitor
Deterioration versus the report thesis
Increased competitive intensity in the long-acting HIV market.
Monitor
Deterioration versus the report thesis
Failure to efficiently deploy free cash flow into accretive acquisitions.
Monitor
Deterioration versus the report thesis
§3 Finanzielle Historie
Gewinn- und Verlustrechnung — letzte sechs Perioden
Position
T−0
T−1
T−2
T−3
T−4
CAGR
Periode
2021-12-31
2022-12-31
2023-12-31
2024-12-31
2025-12-31
Trend
Umsatz
$27.31B
$27.28B
$27.12B
$28.75B
$29.44B
+1.9%
Bruttogewinn
$20.70B
$21.62B
$20.62B
$22.50B
$23.21B
+2.9%
Betriebsergebnis
$10.86B
$10.97B
$8.84B
$10.60B
$11.70B
+1.9%
Nettogewinn
$6.23B
$4.59B
$5.67B
$480.0M
$8.51B
+8.1%
EPS (verwässert)
$4.93
$3.64
$4.50
$0.38
$6.78
+8.3%
EBITDA
$11.33B
$8.85B
$10.50B
$4.43B
$13.58B
+4.6%
F&E
$4.60B
$4.98B
$5.72B
$5.91B
$5.80B
+6.0%
VVG
$5.25B
$5.67B
$6.06B
$6.00B
$5.71B
+2.1%
Qualitäts-Scores
Piotroski F-Score
8 / 9
0–9 Qualitätskomposit
Altman Z-Score
4.3
Insolvenzrisiko (>3 sicher)
Beneish M-Score
-2.45
Risiko von Ergebnismanipulation
OCF / Nettogewinn
1.18×
>1 weist auf hohe Ergebnisqualität hin
Bilanzqualitätsschwelle
Pass
Sektoradjustierte Schwelle
ROIC
2.9%
Rendite auf eingesetztes Kapital
Abschnitt 3
Numbers analysis
Cashflow
Cash-flow quality is reflected in the OCF / net income, accounting-quality, and ROIC rows above.
Kapitalallokation
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
Einzelabonnenten — ab §411 weitere Abschnitte
Vollständige Analyse lesen — 11 weitere Abschnitte.
Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.
Vollständiger Bericht für jeden abgedeckten Ticker
Based on our latest independent analysis, GILD trades close to fair value. The current price is $134 versus a composite fair-value midpoint of $132 (range $103–$163), which implies roughly 1.2% downside to the midpoint.
Our composite fair-value range for GILD is $103–$163, with a midpoint of $132. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for Gilead Sciences Inc.'s archetype.
Our current rating for GILD is Hold with a confidence score of 88/100. Hold. The synthesized fair value of $132.47 aligns closely with the current market price of $134.06. Upside is limited without significant pipeline success, but downside is protected by a strong fundamental yield. This is independent research for educational purposes, not personalized investment advice.
The top risks our latest report flags for Gilead Sciences Inc. are: Biktarvy LOE Collapse; Oncology Pipeline Failure; Aggressive Pricing Reform. The single biggest risk is Biktarvy LOE Collapse: Rapid market share loss following the loss of exclusivity for Biktarvy without adequate replacement from the oncology pipeline.
Our current rating for GILD is Hold, issued with a confidence score of 88/100 and a moat score of 6.5/10. The rating reflects the composite fair-value range ($103–$163) versus the current price of $134.
Gilead Sciences Inc. is classified as a mature-dividend stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for GILD.
